Idera Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Idera Pharmaceuticals, Inc.
Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.
Neuraxpharm Rebrands Spanish Subsidiary As It Focuses On European Profile
Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.
In Vivo’s 2023 Rising Leaders: Healthcare Innovators At The Top Of Their Game
The fourth annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in healthcare.
From Public Funds To VCs: Swiss Financing For Swiss Biotech
While most of the cash for Swiss biotech firms comes from outside the country, around 20% is provided by Swiss entities. Scrip spoke with two of these home-grown supporters of life sciences innovation about the move from academia to industry and their respective investment strategies.
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- Hybridon Inc.
- Idera Pharmaceuticals, Inc.
- Idera Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.